Article ; Online: Serial KL-6 measurements in COVID-19 patients.
Internal and emergency medicine
2021 Volume 16, Issue 6, Page(s) 1541–1545
Abstract: ... of KL-6 in hospitalized COVID-19 patients may contribute to identify severe patients requiring ... behavior in COVID-19 patients to investigate its potential role in predicting clinical course. Sixty ... patients (median age IQR, 65 (52-69), 43 males), hospitalized for COVID-19 at Siena COVID Unit ...
| Abstract | SARS-CoV2-induced direct cytopathic effects against type II pneumocytes are suspected to play a role in mediating and perpetuating lung damage. The aim of this study was to evaluate serum KL-6 behavior in COVID-19 patients to investigate its potential role in predicting clinical course. Sixty patients (median age IQR, 65 (52-69), 43 males), hospitalized for COVID-19 at Siena COVID Unit University Hospital, were prospectively enrolled. Twenty-six patients were selected (median age IQR, 63 (55-71), 16 males); all of them underwent follow-up evaluations, including clinical, radiological, functional, and serum KL-6 assessments, after 6 (t1) and 9 (t2) months from hospital discharge. At t0, KL-6 concentrations were significantly higher than those at t1 (760 (311-1218) vs. 309 (210-408) p = 0.0208) and t2 (760 (311-1218) vs 324 (279-458), p = 0.0365). At t0, KL-6 concentrations were increased in patients with fibrotic lung alterations than in non-fibrotic group (755 (370-1023) vs. 305 (225-608), p = 0.0225). Area under the receiver operating curve (AUROC) analysis showed that basal KL-6 levels showed good accuracy in discriminating patients with fibrotic sequelae radiologically documented (AUC 85%, p = 0.0404). KL-6 concentrations in patients with fibrotic involvement were significantly reduced at t1 (755 (370-1023) vs. 290 (197-521), p = 0.0366) and t2 (755 (370-1023) vs. 318 (173-435), p = 0.0490). Serum concentrations of KL-6 in hospitalized COVID-19 patients may contribute to identify severe patients requiring mechanical ventilation and to predict those who will develop pulmonary fibrotic sequelae in the follow-up. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Aged ; Biomarkers/blood ; COVID-19/blood ; COVID-19/immunology ; Disease Progression ; Humans ; Male ; Middle Aged ; Mucin-1/blood ; Prognosis ; SARS-CoV-2/pathogenicity ; Severity of Illness Index | |||||
| Chemical Substances | Biomarkers ; MUC1 protein, human ; Mucin-1 | |||||
| Language | English | |||||
| Publishing date | 2021-01-16 | |||||
| Publishing country | Italy | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 2454173-4 | |||||
| ISSN | 1970-9366 ; 1828-0447 | |||||
| ISSN (online) | 1970-9366 | |||||
| ISSN | 1828-0447 | |||||
| DOI | 10.1007/s11739-020-02614-7 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6673: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.